Molecular antimicrobial resistance surveillance for Neisseria gonorrhoeae, Northern Territory, Australia

David Whiley, Ella Trembizki, Cameron Buckley, Kevin Freeman, Robert Baird, Miles Beaman, Marcus Chen, Basil Donovan, Ratan Kundu, Christopher Fairley, Rebecca Guy, Tiffany Hogan, John Kaldor, Mahdad Karimi, Athena Limnios, David Regan, Nathan Ryder, Jiunn-Yih Su, James Ward, Monica Lahra

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Neisseria gonorrhoeae antimicrobial resistance (AMR) is a globally recognized health threat; new strategies are needed to enhance AMR surveillance. The Northern Territory of Australia is unique in that 2 different first-line therapies, based primarily on geographic location, are used for gonorrhea treatment. We tested 1,629 N. gonorrhoeae nucleic acid amplification test–positive clinical samples, collected from regions where ceftriaxone plus azithromycin or amoxicillin plus azithromycin are recommended first-line treatments, by using 8 N. gonorrhoeae AMR PCR assays. We compared results with those from routine culture-based surveillance data. PCR data confirmed an absence of ceftriaxone resistance and a low level of azithromycin resistance (0.2%), and that penicillin resistance was <5% in amoxicillin plus azithromycin regions. Rates of ciprofloxacin resistance and penicillinase-producing N. gonorrhoeae were lower when molecular methods were used. Molecular methods to detect N. gonorrhoeae AMR can increase the evidence base for treatment guidelines, particularly in settings where culture-based surveillance is limited.

Original languageEnglish
Pages (from-to)1478-1485
Number of pages8
JournalEmerging Infectious Diseases
Issue number9
Publication statusPublished - Sept 2017


Dive into the research topics of 'Molecular antimicrobial resistance surveillance for Neisseria gonorrhoeae, Northern Territory, Australia'. Together they form a unique fingerprint.

Cite this